The latest news from academia, regulators
research labs and other things of interest
Posted: Jun 17, 2013
EU launches Nanomedicine Award for the best international nanomedicine innovation
(Nanowerk News) The goal of the Nanomedicine Award 2013 is to recognize innovative nanomedicine-based solutions that could help physicians change the way diseases are treated and diagnosed, bringing significant benefits to patients.
The Award is open to companies, academic and private researchers across the globe. Nominated projects should represent new diagnostic and therapeutic approaches that address unmet medical needs, are not feasible without nanotechnology, are clearly distinct from standard approaches and have an explicit defined potential market.
Projects will be evaluated on the basis of being either a concept or a preclinical or clinical application in nanotherapeutics, diagnostic or regenerative medicine. Applications will be reviewed and assessed by a panel of highly-qualified pharma industry specialists with experience in R&D and commercial roles: Laurent Levy, Nanobiotix; Neil Desai, Celgene; Mike Eaton, consultant; Patrick Tricoli, Sanofi; Karen Zinkevich-Peotti, Ipsen and Thorsten Melcher, Johnson & Johnson Innovation.
The Award is supported by the EBD Group, the leading partnering firm for the global life science industry, and Nanobiotix, a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The presentation of the Award will take place during the Nanomedicine Panel Discussion at BIO-Europe 2013 in Vienna, Austria, on 4th November 2013.
The winners will receive media coverage across Europe and gain visibility to EU decision makers from biotechnology, pharma, academia and finance. Winners will also benefit from a full registration (including partnering) for BIO-Europe 2013 and a 5 minute presentation slot at the Nanomedicine Panel Discussion during the event. In addition, the winning project will also be granted a 15 minute presentation slot during the CLINAM conference 2014 in Basel, Switzerland, along with 1 year’s free ETPN membership and two days consultation by the members of the ETPN Translational Advisory Board.
Entries for nominations for the Award will be open from 6th June to 7th September 2013. The application form is available online.
About ETP Nanomedicine
The European Technology Platform Nanomedicine was established in 2005 as a joint venture of the European Commission and CEOs of large industrial companies, SMEs and academic research institutions to investigate and advance joint activities in the area of nanotechnology in medicine. Since 2005 the ETPN published a number of strategic documents outlining the needs and roadmaps for nanomedicine research in Europe. The ETPN contributed to set up numerous European funded projects providing a first impression of the conditions for a suitable social and economic environment and the structural requirements for an efficient translation of R&D results into innovative nanomedicine. The ETPN supports its members in coordinating their joint research efforts and improving communication amongst the members as well as towards the European Commission and the European Member States.
If you liked this article, please give it a quick review on reddit or StumbleUpon. Thanks!